This vaccine is suitable for inhabitants of epidemic areas of hemorrhagic fever with renal syndrome (HFRS) and people entering such areas, and mainly targets the high-risk group aged between 16 and 60. After vaccination, it can stimulate the body to develop immunity against type I and type II HFRS viruses. It is used to prevent type I and type II HFRS. 1.0 ml per vial.